Amal Therapeutics SA is a privately held Swiss/German biotech start-up company and spin-off from the University of Geneva.
AMAL has raised €29M across 1 funding round from 1 investor, most recently a Series B round in Nov 2018. Based in Geneva, Switzerland; founded 2012; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2018-11-12 | Series B | €29M |
| Boehringer Ingelheim Venture Fund |
| View deal → |
